Bridging the Alzheimer's Translational Gap

Despite decades of investment, Alzheimer’s remains one of the most challenging areas in drug development. Understanding why some assets successfully translate from preclinical research to clinical efficacy has become a critical question for neuroscience R&D teams.

Bridging the Alzheimer’s Translational Gap examines more than 1,500 Alzheimer’s-associated programmes to identify the characteristics linked with successful progression from preclinical validation to clinical proof-of-concept.

This report explores how factors such as disease-stage alignment, preclinical model selection, CNS target engagement and functional efficacy evidence influence translational outcomes, complete with preclinical and clinical data from select Alzheimer asset examples.